A Comparative Study Assessing the Incidence and Degree of Hyperkalemia in Patients on Unfractionated Heparin versus Low-Molecular Weight Heparin.

Background: Heparin and its derivates, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH), are among the most commonly used anticoagulants. Nonetheless, their use has been associated with hyperkalemia. Objective: To determine and compare the incidence, magnitude, and potential risk factors of hyperkalemia in patients receiving UFH versus LMWH in a real-world clinical setting. Methods: A retrospective observational study was conducted involving all adult hospitalized patients who received UFH, dalteparin or enoxaparin. Electronic medical records were reviewed over a 12-month period, collecting data on demographic, laboratory, comorbidity, and medication-related variables. Data were analyzed using multivariate logistic regression. Results: A total of 929 patients met the eligibility criteria, with a mean age of over 40 years across all groups. Of these, 56.3%, 17.2%, and 15.7% experienced hyperkalemia with UFH, dalteparin and enoxaparin, respectively. The incidence of hyperkalemia was significantly higher with UFH compared to enoxaparin and dalteparin (p<0.001). Diabetes mellitus was associated with a higher incidence of hyperkalemia (OR 1.79, 95% CI 1.241-2.581, p=0.002), as was the concomitant use of co-trimoxazole (OR 2.244, 95% CI 1.137-4.426, p=0.02). Whilst chronic kidney disease and the use of two or more hyperkalemia-inducing agents were not statistically significant, they were retained in the model as they were associated with more than a 10% increase in the odds of hyperkalemia. Conclusion: Heparin (UFH, LMWH) administration was associated with a risk of hyperkalemia particularly in patients with diabetes mellitus and those concurrently receiving co-trimoxazole.